Search
Dequalinium
go.drugbank.com/drugs/DB04209ApprovedDue to its flexible structure, dequalinium was investigated to build drug and gene delivery systems. … Dequalinium is an antibacterial agent with multi-targeted actions. It also possesses antifungal, antiparasitic, antiviral, anticancer, and neuroprotective properties.
Products: D-COOLMethotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients
Products: TRIXILEM RU, TRIXILEM®RU SOLUCION INYECTABLEPafolacianine
go.drugbank.com/drugs/DB15413ApprovedInvestigational[A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.
Norethisterone
go.drugbank.com/drugs/DB00717ApprovedInvestigationalL9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an
Eplerenone
go.drugbank.com/drugs/DB00700ApprovedInvestigationalThe resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. … Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative
Idecabtagene vicleucel
go.drugbank.com/drugs/DB16665ApprovedInvestigational[A232563] Multiple myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor like [bortezomib], or an anti-CD38 monoclonal antibody like [isatuximab … [A232558] The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain.
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.
Dihydrotachysterol
go.drugbank.com/drugs/DB01070ApprovedWithdrawnA vitamin D that can be regarded as a reduction product of vitamin D2.
Categories: Vitamin D and AnaloguesCarglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalThis rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death.